Systematic review and meta-analysis of shenqi fuzheng and chemotherapy combination in the treatment of breast cancer

Authors

  • Ying Li Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450-000
  • Na Han Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450-000
  • Zhuo Chen Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450-000
  • Xing Li Department of Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450-000

DOI:

https://doi.org/10.3329/bjp.v11i4.27200

Keywords:

Breast cancer, Chemotherapy, Meta-analysis, Shenqi fuzheng

Abstract

This review evaluates the effectiveness and safety of injection of shenqi fuzheng with chemotherapy in the treatment of breast cancer in China. The study included 20 randomized clinical trials (RCTs) involving 1,609 patients. It was shown that shenqi fuzheng could improved the treatment efficiency, Kamofsky Performance Status (KPS), weight and autoimmune; reduced fatigue, gastrointestinal reaction and the toxicity of bone marrow; protected liver, kidney and heart from damage by chemotherapy. However, the quality of all the studies was relatively low and there was great heterogeneity between various studies. Further well-designed research is needed to estimate the beneficial effects of shenqi fuzheng.

Downloads

Download data is not yet available.
Abstract
94
Download
50 Read
22

References

Ai Q, Zhang W, Xie Y, Huang W, Liang H, Cao H. Post-marketing safety monitoring of shenqifuzheng injection: A solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici). J Tradit Chin Med. 2014; 34: 498-503.

Bo Y, Li HS, Qi YC, Lu MY. Clinical study on treatment of mammary cancer by shenqi fuzheng injection in cooperation with chemotherapy. Chin J Integr Med. 2007; 13: 37-40.

Chen F, Lin H. Clinical observation of shenqifuzheng injection in assist chemotherapy of breast cancer. Strait Pharma-ceutical J. 2007; 19: 75-76.

Chen JM X X H, L H. Clinical observation of shenqifuzheng injection in the treatment of advanced breast cancer patients with chemotherapy. Mod J Integ Trad Chin West Med. 2010; 19: 2651-52.

Cui YZ, ZSJHYG. Shenqifuzheng injection prevented anthracycline cardiotoxicity. Hebei Med J. 2010: 1685-86.

Dai Zj WXJ. Clinical observation of efficacy and adverse reactions on Shenqifuzheng injection used in patients with breast cancer receiving neoadjuvant chemotherapy. ADRJ. 2010: 10-14.

Deng Y, Chen HF. Effects of Astragalus injection and its ingredients on proliferation and Akt phosphorylation of breast cancer cell lines. Zhong Xi Yi Jie He Xue Bao. 2009; 7: 1174-80.

Horton JK, Siamakpour-Reihani S, Lee CT, Zhou Y, Chen W, Geradts J, Fels DR, Hoang P, Ashcraft KA, Groth J, Kung HN, Dewhirst MW, Chi JT. FAS death receptor: A breast cancer subtype-specific radiation response biomarker and potential therapeutic target. Radiat Res. 2015; 184: 456-69.

Huang ZF, Wei JS, Li HZ. Effect of Shenqi Fuzheng injection combined with chemotherapy on thirty patients with advanced breast cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008: 28: 152-54.

Kawuli. Curative effect observation: Shenqifuzheng injection in the treatment of advanced breast cancer patients with chemotherapy. Guide China Med. 2010: 885-86.

Lee E, Menon U, Nandy K, Szalacha L, Kviz F, Cho Y, Miller A, Park H. The effect of a couples intervention to increase breast cancer screening among korean americans. Oncol Nurs Forum. 2014; 41: E185-93.

Li C, Yang G, Yu M, Xu Y, Xue N, Nan N, Wang X. Effects of traditional Chinese medicine Shu Gan Jian Pi granules on patients with breast cancer and cancer-related fatigue: Study protocol for a randomized controlled trial. Trials 2015; 16: 192.

Li Xl. Clinical observation of shenqifuzheng injection treated advanced breast cancer patients with chemotherapy. Mod Oncol. 2010: 574-75.

Li YQ. 35 cases of Shenqifuzheng injection treated advanced breast cancer patients with chemotherapy. J Chin Integr Med. 2010: 827.

Lie JY. Shenqifuzheng injection in the treatment of ? advanced breast cancer patients influence on the serum CA153 and activity of immune cell with chemotherapy. J Practical Oncol. 2010: 885-86.

Lin SQ, Wei XH, Huang P, Liu YY, Zhao N, Li Q, Pan CS, Hu BH, Chang X, Fan JY, Yang XY, Wang CS, Liu HN, Han JY. QiShenYiQi Pills(R) prevent cardiac ischemia-reperfusion injury via energy modulation. Int J Cardiol. 2013; 168: 967-74.

Lu CY, Chen XY. Progress of research on apoptosis of breast cancer cells. Zhong Xi Yi Jie He Xue Bao. 2003; 1: 226-29.

Lu MY. The effects of shenqifuzheng injection on the immune function of patients with breast cancer treated with CAF regimen chemotherapy. J Basic Clin Oncol. 2010; 23: 236-38.

McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, Kannourakis G, Francis PA, Chirgwin J, Abdi E, Gebski V, Veillard AS, Zannino D, Wilcken N, Reaby L, Lindsay DF, Badger HD, Forbes JF. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). Breast. 2014; 23: 142-51.

Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010; 63: e1-37.

Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012; 10: 28-55.

Pu Z, Yuan X, Zhang X, Chen Q, Xie H. Meta-analysis on the association between CYP2D6*10 gene polymorphism and disease free survival of breast cancer patients receiving tamoxifen treatment in Asia. Bangladesh J Pharmacol. 2014; 9.

Pu Z, Zhang X, Chen Q, Yuan X, Xie H. Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cells. Oncol Rep. 2015; 33: 2420-28.

Raia-Barjat T, Trombert B, Khaddage A, Douchet C, Seffert P, Peoc'h M, Falk AT, Magne N, Chauleur C. OSNA (one-step nucleic acid amplification) sentinel lymph node intraoperative molecular analysis in breast cancer: A cost-benefit analysis. Med Oncol. 2014; 31: 322.

Sanchez R, St-Cyr J, Lalonde ME, Healy J, Richer C, Gagne V, Laverdiere C, Silverman LB, Sallan SE, Neuberg D, Kutok JL, Kritikou EA, Krajinovic M, Sinnett D. Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia. Haematologica 2014; 99: 314-21.

Schmidt T, Weisser B, Durkop J, Jonat W, Van Mackelenbergh M, Rocken C, Mundhenke C. Comparing endurance and resistance training with standard care during chemotherapy for patients with primary breast cancer. Anti-cancer Res. 2015; 35: 5623-29.

Schulz KF. Assessing allocation concealment and blinding in randomised controlled trials: Why bother? Evid Based Nurs. 2001; 4: 4-6.

Shui Y, Tang Y, Zhang X, Ge J, Pu Z. Adjuvant chemotherapy of megestrol acetate in advanced breast cancer: A meta-analysis. Bangladesh J Pharmacol. 2015; 10: 383.

Sun XZ. Curative effect of shenqifuzheng injection treated advanced breast cancer patients with chemotherapy. J China Trad Chin Med Inform. 2011; 3: 237.

Valadares F, Garbi Novaes MR, Canete R. Effect of Agaricus sylvaticus supplementation on nutritional status and adverse events of chemotherapy of breast cancer: A randomized, placebo-controlled, double-blind clinical trial. Indian J Pharmacol. 2013; 45: 217-22.

von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 1269-78.

Wang SM. The application: Shenqifuzheng injection in the treatment of advanced breast cancer patients with chemotherapy. Med Industry Inform. 2006; 3: 124.

Xiao HW. Shenqifuzheng injection combined with FEC in the treatment of breast carcinoma. J Med Theor Prac. 2005; 18: 885-86.

Xie W, Zhao Y, Zhang Y. Traditional chinese medicines in treatment of patients with type 2 diabetes mellitus. Evid Based Complement Alternat Med. 2011; 2011: 723-26.

Xu HJ. Clinical research of Shenqifuzheng injection reduced the cardiac toxicity of breast cancer with TA. Chinese community doctors. 2010; 36: 130.

Xu NL. The effects of Shenqifuzheng injection on the immune function of patients with breast cancer treated with chemotherapy. Henan Medical Information. 2003; 24: 12.

Yao K, Ma Y, Ma W, Hu J, Wang C, Chen J, Zhang J, Hua L, Ren X. Shenqifuzheng injection combined with chemotherapy in the treatment of advanced gastric cancer: A systematic review and meta-analysis. J Cancer Res Ther. 2014; 10 Suppl 1: 70-74.

Ye MN, Chen HF. Effects of Astragalus injection on proliferation of basal-like breast cancer cell line MDA-MB-468. Zhong Xi Yi Jie He Xue Bao. 2008; 6: 399-404.

Yuan JW, Kong CB, Kang GQ, Liu XF, Yang SJ. Effects of neoadjuvant chemotherapy combined with shenqifuzheng injection on cell immune function patients with breast cancer. Lishizhen Med Mater Res. 2008; 19: 1099-100.

Ze Y. Shenqifuzheng injection treated advanced breast cancer patients with chemotherapy. Shandong Med J. 2011; 51: 109.

Zhang RL. The role of chemotherapy: Shenqi fuzheng injection on the immune function of patients with breast cancer. J medical forum. 2004; 25: 48.

Zhu K. Clinical observation of shenqi fuzheng injection in the treatment of advanced breast cancer patients with chemotherapy. J Mod Oncol. 2010; 19: 2651-52.

Zou TL. The attenuation of shenqi fuzheng injection treated advanced breast cancer patients with chemotherapy. J Pract Oncol. 2006; 21: 75-77.

Downloads

Additional Files

Published

2016-10-01

How to Cite

Li, Y., N. Han, Z. Chen, and X. Li. “Systematic Review and Meta-Analysis of Shenqi Fuzheng and Chemotherapy Combination in the Treatment of Breast Cancer”. Bangladesh Journal of Pharmacology, vol. 11, no. 4, Oct. 2016, pp. 793-01, doi:10.3329/bjp.v11i4.27200.

Issue

Vol. 11 No. 4 (2016)

Section

Meta-Analysis

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).